Key result
Postdiagnosis aspirin therapy improved overall survival in colorectal cancer patients (HR 0.84; 95% CI 0.75-0.94), especially those with positive PTGS2 expression or mutated PIK3CA tumors.
Why the study?
Does aspirin use before or after diagnosis improve survival in patients with colorectal cancer?
Population
Patients with colorectal cancer from 14 studies
Comparison
Aspirin use (either prediagnosis or postdiagnosis) vs No aspirin use
Design
Meta-analysis
Authors
Loading...
May support postdiagnosis aspirin in PTGS2-positive or PIK3CA-mutated colorectal cancer; extends biomarker stratification evidence but requires RCTs.
Meta-Analysis
Does aspirin use before or after diagnosis improve survival in patients with colorectal cancer?
Effect estimate: HR 0.84 (95% CI 0.75-0.94)
Postdiagnosis aspirin therapy improves overall survival in colorectal cancer patients, particularly those with positive PTGS2 (COX-2) expression and mutated PIK3CA tumors.
Li et al. (2014) conducted a meta-analysis in Colorectal cancer (CRC). Aspirin was evaluated on Overall mortality (HR 0.84, 95% CI 0.75-0.94). Postdiagnosis aspirin therapy improved overall survival in colorectal cancer patients (HR 0.84; 95% CI 0.75-0.94), especially those with positive PTGS2 expression or mutated PIK3CA tumors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: